GlassScriptPhysician profile
Scarlin A Rhoades
NPI 1033937503
$1,658.74
in general payments reported to CMS, 2019-2025
22 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.26 |
| Education | $292.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $695.89 | 2025 | Trodelvy |
| Incyte Corporation | $205.63 | 2025 | Jakafi, Zynyz, Monjuvi |
| Pharmacosmos Therapeutics INC. | $136.49 | 2025 | Monoferric |
| Daiichi Sankyo INC. | $100.60 | 2025 | Enhertu, Vanflyta, Datroway |
| Novartis Pharmaceuticals Corporation | $79.02 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.15 | 2025 | Opdivo |
| Eisai INC. | $42.84 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $41.96 | 2025 | Enhertu |
| Janssen Biotech, INC. | $36.09 | 2025 | Darzalex, Balversa, Erleada |
| Abbvie INC. | $33.79 | 2025 | |
| Adaptive Biotechnologies Corporation | $24.99 | 2025 | Clonoseq |
| Sobi, INC | $23.75 | 2025 | |
| Azurity Pharmaceuticals, INC. | $20.92 | 2025 | Vivimusta, Danziten |
| Glaxosmithkline, LLC. | $20.61 | 2025 | Jemperli, Zejula |
| Deciphera Pharmaceuticals INC. | $20.39 | 2025 | Qinlock, Romvimza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.25 | 2025 | Polivy |
| Taiho Oncology, INC. | $19.04 | 2025 | |
| Genzyme Corporation | $18.99 | 2025 | |
| Pharmaessentia USA Corporation | $18.75 | 2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $17.99 | 2025 | Libtayo |
| Emd Serono, INC. | $15.35 | 2025 | |
| Genmab U.S., INC. | $15.25 | 2025 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scarlin Rhoades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.